Shengnuo Biotech announced that Meishan Huilong Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the “Certificate for Exporting APIs to the EU” approved and issued by the Sichuan Drug Administration. It involves tiverpotide APIs. The certification is valid until October 11, 2029. The Meishan Huilong tiberpeptide API production line has passed on-site inspection. Its production quality management system complies with China's GMP requirements, and is equivalent to meeting the European Union, World Health Organization, and ICHQ7 drug GMP standards.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.